Aktis Oncology, Inc. (AKTS) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $258.6K sold). Latest close $16.10 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 23, 2026 · Congress to Nov 16, 2026.
RTW Investments · RA Capital Management · Baker Bros. Advisors — 4 tracked funds hold AKTS. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 2 sales ($258.6K). Insider trading
Kodiak Sciences Inc. (KOD) · EVOMMUNE INC (EVMN) · Wave Life Sciences, Inc. (WVE) · XENCOR INC (XNCR) · Taysha Gene Therapies, Inc. (TSHA) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| RTW Investments | 0.44% | 1,592,043 | HELD Q3 filed Nov 16 |
| RA Capital Management | 0.37% | 1,314,405 | TRIMMED (-12.6%) Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.16% | 996,351 | HELD Q3 filed Nov 16 |
| Polen Capital Management | 0.02% | 63,514 | NEW Q3 filed Nov 13 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -47.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 217 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 114 of 8,857 filers |
| Long-only filers among them | 114 |
| Change vs 2026 Q1 | +49 net · 113 entered · 64 exited |
| Shares reported, all filers | 34,170,226 |
| Reported value, all filers | $1.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Shares outstanding | 53,446,222 |
| Market cap (at latest close) | $860.5M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jun 30, 2026.
| Shares short · Oct 15, 2026 | 4,313,744 |
| Share of shares outstanding | 8.07% |
| Days to cover | 11.27 |
Shares short at recent settlements — Jul 31, 2026: 3.5M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.2M · Sep 15, 2026: 3.3M · Sep 30, 2026: 4.7M · Oct 15, 2026: 4.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jun 30, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jun 30, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 1 insider ($258.6K).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | Sell | 5,099 | $20.19 | $103.0K | SEC filing |
| Sep 23, 2026 | Czibere Akos | Chief Medical Officer | Sell | 7,401 | $21.03 | $155.6K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Akos Czibere | Officer | 25,000 | $552.8K | Sep 23, 2026 | SEC filing |
| Jul 20, 2026 | KEN HERRMANN | Director | 4,856 | $119.3K | Jul 20, 2026 | SEC filing |
| Jul 17, 2026 | KEN HERRMANN | Director | 3,065 | $77.3K | Jul 17, 2026 | SEC filing |
| Jul 8, 2026 | AKOS CZIBERE | Officer | 50,000 | $1.4M | Jul 8, 2026 | SEC filing |
| Jul 8, 2026 | SHULAMIT RON-BIGGER | Officer | 50,000 | $1.4M | Jul 8, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jan 20, 2026 | SCHEDULE 13D | -20.1% (close Jan 21, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jan 21, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Blue Owl Capital Holdings LP | SC 13G | 3,161,348 | 5.9% | Mar 31, 2026 | SEC filing |
| Jan 20, 2026 | MPM BIOVENTURES 2018, L.P. | SC 13D | 3,950,528 | 7.4% | Jan 12, 2026 | SEC filing |
| Jan 20, 2026 | EcoR1 Capital, LLC | SC 13D | 4,824,469 | 9.1% | Jan 12, 2026 | SEC filing |
| Jan 15, 2026 | Eli Lilly and Company | SC 13D | 6,344,114 | 11.9% | Jan 12, 2026 | SEC filing |
| Jan 14, 2026 | Vida Ventures II, LLC | SC 13D | 5,671,825 | 10.6% | Jan 12, 2026 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
This stock does not currently pass any tracked screen.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q1, ranked #3 of 50.
Also held by the tracked funds that hold AKTS — ranked by lift, the co-holding pattern described in Methodology: Kodiak Sciences Inc. (KOD) · EVOMMUNE INC (EVMN) · Wave Life Sciences, Inc. (WVE) · XENCOR INC (XNCR) · Taysha Gene Therapies, Inc. (TSHA) · DISC MEDICINE INC (IRON) · Mirum Pharmaceuticals, Inc. (MIRM) · AVALO THERAPEUTICS INC (AVTX).
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 13, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| May 11, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Kodiak Sciences Inc. (KOD) · Track Record: how the signals scored · Practice timing on AKTS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.